



## LIMITED REVIEW REPORT

To  
The Board of Directors  
Phaarmasia Limited  
Hyderabad.

We have reviewed the accompanying statement of Un-audited financial results of M/s **PHAARMASIA LIMITED, Hyderabad** for the period ended **31<sup>st</sup> December, 2016**. This statement is the responsibility of the Company's Management and has been approved by Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with applicable Accounting Standards and other Recognized Accounting Practices and Policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015 including the manner in which it is to be disclosed, or that it contains any material misstatements.

FOR K.S.RAMAKRISHNA & CO  
CHARTERED ACCOUNTANTS  
Firm Regn. No.002888S

*K. Rama Rao*

(K.RAMA RAO)  
Partner  
M.No.206039



Place: Hyderabad  
Date: 14<sup>th</sup> February'2017

Statement of Standalone Un-Audited Results for the quarter ended 31st December' 2016

SR. NO.	Particulars	Quarter Ended			Year to date figures for current period ended 31-12-2016	Year to date figures for previous year ended 31-12-2015	Year Ended 31-03-2016
		31.12.2016	30.09.2016	31.12.2015			
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	a) Net Sales / Income from Operations (Excluding Branch Transfer, Excise Duty)	375.77	288.83	316.21	944.04	964.42	1315.51
	b) Other Operating Income	12.78	16.58	17.76	45.04	41.81	53.40
	<b>Total Income from operations (net)</b>	<b>388.55</b>	<b>305.41</b>	<b>333.97</b>	<b>989.08</b>	<b>1006.24</b>	<b>1368.91</b>
2	<b>Expenses</b>						
	a. Cost of Material Consumed	140.41	161.10	155.03	430.33	419.96	594.12
	b. Purchase of Traded Goods	9.45	0.00	0.00	9.45	0.00	0.00
	c. Changes in inventories of finished goods, work-in-progress and stock -in-trade	28.85	-37.99	-17.64	-2.10	-19.78	-5.39
	d. Employee benefits expense	41.29	33.90	34.25	106.78	104.91	156.26
	e. Depreciation and Amortisation expense	11.11	10.99	16.42	32.86	47.01	49.56
	f. Other Expenses	146.92	129.28	133.35	386.29	421.51	548.80
	<b>Total Expenses</b>	<b>378.03</b>	<b>297.29</b>	<b>321.42</b>	<b>963.60</b>	<b>973.62</b>	<b>1343.35</b>
3	<b>Profit / (Loss) from Operations before other income, finance costs and exceptional items (1 - 2)</b>	<b>10.51</b>	<b>8.12</b>	<b>12.55</b>	<b>25.48</b>	<b>32.62</b>	<b>25.56</b>
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)</b>	<b>10.51</b>	<b>8.12</b>	<b>12.55</b>	<b>25.48</b>	<b>32.62</b>	<b>25.56</b>
6	Finance Costs	0.32	0.99	0.32	1.55	1.48	1.06
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)</b>	<b>10.20</b>	<b>7.13</b>	<b>12.23</b>	<b>23.93</b>	<b>31.14</b>	<b>24.50</b>
8	Exceptional Items - Expenditure / (Income)	0.00	0.00	0.00	0.00	0.00	0.00
9	<b>Profit / (Loss) from Ordinary Activities before tax (7 ± 8)</b>	<b>10.20</b>	<b>7.13</b>	<b>12.23</b>	<b>23.93</b>	<b>31.14</b>	<b>24.50</b>
10	Add/Less :Tax Expense	-3.06	-2.14	-3.67	-7.18	-9.34	-14.49
	Add/Less : Tax Expenses-Earlier Years	0.00	0.00	0.00	0.00	0.00	-5.83
11	<b>Net Profit / (Loss) from Ordinary Activities after tax (9 ± 10)</b>	<b>7.14</b>	<b>4.99</b>	<b>8.56</b>	<b>16.75</b>	<b>21.80</b>	<b>4.18</b>
12	Extraordinary items (Net of Tax expense Rs. Nil)	0.00	0.00	0.00	0.00	0.00	0.00
13	<b>Net Profit / (Loss) for the period (11 ± 12)</b>	<b>7.14</b>	<b>4.99</b>	<b>8.56</b>	<b>16.75</b>	<b>21.80</b>	<b>4.18</b>
14	Share of Profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00
16	<b>Net/(loss) after taxes, minority interest and share of profit/(loss) of associates(13±14±15)*</b>	<b>7.14</b>	<b>4.99</b>	<b>8.56</b>	<b>16.75</b>	<b>21.80</b>	<b>4.18</b>
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	682.70	682.70	682.70	682.70	682.70	682.70
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	96.97	89.84	76.05	96.97	76.05	80.23
19 i	<b>Earnings Per Shares (before extraordinary items)</b>						
	(a) Basic	0.10	0.07	0.125	0.25	0.319	0.06
	(b) Diluted	0.10	0.07	0.125	0.25	0.319	0.06
19 ii	<b>Earning Per Share (after extraordinary items) (of Rs. 10/0 (not annualised):</b>						
	(a) Basic	0.10	0.07	0.125	0.25	0.319	0.06
	(b) Diluted	0.10	0.07	0.125	0.25	0.319	0.06
	See accompanying note to the Financial Results						

Notes:

- The above un-audited Financial results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at its meeting held on 14.02.2017
- The Company operates primarily in the Pharmaceuticals Business and Hence has only one reportable segment.
- Figures for the previous periods have been regrouped/rearranged wherever necessary.

14.02.2017



for PHAARMASIA LIMITED

Y.N.Bhaskar Rao  
Whole - Time Director  
DIN: 00019052